胜肽類抗生素市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、給藥途徑、配銷通路、地區和競爭細分，2020-2030 年預測

2024 年全球胜肽類抗生素市場價值為 51.7 億美元，預計到 2030 年將達到 76.7 億美元，預測期內複合年成長率為 6.79%。肽類抗生素是具有抗菌特性的短鏈胺基酸，用於治療各種傳染病。與傳統的小分子抗生素不同，肽類抗生素由較大的類似蛋白質的分子組成，並透過膜破壞或干擾細菌複製等多種機制發揮作用。他們的多目標方法降低了細菌抗藥性的可能性，這在抗生素抗藥性不斷上升的時代是一個關鍵優勢。耐甲氧西林金黃色葡萄球菌 (MRSA) 等感染的日益流行、人口老化、外科手術的增加以及胜肽合成技術的增強都導致了對這些藥物的需求增加。此外，胜肽類抗生素擴大被用作管理計劃的一部分以及醫療保健中的預防應用，從而加強了其在現代傳染病管理中不斷擴大的作用。

關鍵市場促進因素

肽合成的進展

主要市場挑戰

開發成本高

主要市場趨勢

抗菌肽（AMP）的認知度不斷提高

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球胜肽類抗生素市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依類型（非核醣體合成胜肽抗生素、核醣體合成胜肽抗生素）
  • 依給藥途徑（注射、口服、外用）
  • 按配銷通路（醫院藥房、網路藥房和零售藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：亞太胜肽類抗生素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第7章：歐洲胜肽類抗生素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第8章：北美胜肽類抗生素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第9章：南美洲胜肽類抗生素市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲胜肽抗生素市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球胜肽抗生素市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Pfizer Inc.
• Merck & Co., Inc.
• AbbVie Inc
• GSK Plc
• Sandoz International GmbH
• Xellia Pharmaceuticals
• AuroMedics Pharma LLC
• The Menarini Group
• Teva Pharmaceutical Industries Ltd.
• Novartis AG

第 17 章：策略建議

第18章調查會社について,免責事項

The Global Peptide Antibiotics Market was valued at USD 5.17 Billion in 2024 and is projected to reach USD 7.67 Billion by 2030, growing at a CAGR of 6.79% during the forecast period. Peptide antibiotics are short chains of amino acids with antimicrobial properties, used in the treatment of various infectious diseases. Unlike traditional small-molecule antibiotics, peptide antibiotics consist of larger, protein-like molecules and operate through diverse mechanisms such as membrane disruption or interference with bacterial replication. Their multi-targeted approach reduces the likelihood of bacterial resistance, a key advantage in an era marked by rising antimicrobial resistance. The growing prevalence of infections like Methicillin-resistant Staphylococcus aureus (MRSA), aging populations, increased surgical procedures, and enhanced peptide synthesis technologies are all contributing to the increased demand for these drugs. Moreover, peptide antibiotics are being increasingly used as part of stewardship programs and in prophylactic applications in healthcare, reinforcing their expanding role in modern infectious disease management.

Key Market Drivers

Advancements in Peptide Synthesis

Progress in solid-phase peptide synthesis (SPPS) has significantly enhanced the scalability and efficiency of peptide antibiotic production. Techniques such as the use of Fmoc and Boc protecting groups, multi-segment synthesis, and continuous-flow systems have streamlined complex peptide assembly. Automation has also become prevalent, enabling high-throughput synthesis with precision control. These technological innovations allow for cost-effective and rapid production of complex and stable peptides with enhanced bioactivity. Strategies like native chemical ligation and peptide cyclization further contribute to increased therapeutic efficacy and resistance to enzymatic degradation. Improvements in purification and conjugation methods, as well as the integration of peptides into nanoparticle systems, are expanding the applications of peptide antibiotics in targeted drug delivery and diagnostics, fueling their market expansion.

Key Market Challenges

High Development Costs

The development of peptide antibiotics involves substantial investment across preclinical research, clinical trials, regulatory compliance, and large-scale manufacturing. Early-stage discovery and testing of new peptide candidates demand significant funding for laboratory infrastructure, skilled personnel, and animal studies. Clinical trials-particularly in later stages-incur major costs due to patient recruitment, monitoring, and data collection. Regulatory processes also impose strict requirements for demonstrating safety, efficacy, and quality, further adding to development expenses. Additionally, the cost of peptide production, especially at commercial scale, is elevated due to the complexity of synthesis, quality assurance protocols, and the need for specialized manufacturing equipment. Intellectual property management and ongoing pharmacovigilance activities also contribute to the financial burden, making cost a significant hurdle for widespread adoption.

Key Market Trends

Growing Awareness of Antimicrobial Peptides (AMPs)

Antimicrobial peptides (AMPs) are gaining recognition for their broad-spectrum antimicrobial properties and unique mechanisms of action. Sourced from various organisms, AMPs target a wide range of pathogens and exhibit low resistance development potential. Their dual role in microbial eradication and immune modulation enhances their appeal in infectious disease treatment. The integration of AMPs with traditional antibiotics is being explored to improve therapeutic outcomes and limit resistance. Their application is also expanding into wound care and dermatology due to their healing properties. Increased R&D investment by pharmaceutical companies and a focus on developing AMP-based alternatives to conventional antibiotics reflect the market's shift toward innovative and sustainable antimicrobial solutions.

Key Market Players

• Pfizer Inc.
• Merck & Co., Inc.
• AbbVie Inc
• GSK Plc
• Sandoz International GmbH
• The Menarini Group
• Xellia Pharmaceuticals
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• AuroMedics Pharma LLC

Report Scope:

In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Antibiotics Market, By Type:

• Non-Ribosomal Synthesized Peptide Antibiotics
• Ribosomal Synthesized Peptide Antibiotics

Peptide Antibiotics Market, By Route of Administration:

• Injectable
• Oral
• Topical

Peptide Antibiotics Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Peptide Antibiotics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.

Available Customizations:

Global Peptide Antibiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Antibiotics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
  • 5.2.2. By Route of Administration (Injectable, Oral, Topical)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Peptide Antibiotics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Peptide Antibiotics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. India Peptide Antibiotics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Australia Peptide Antibiotics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Japan Peptide Antibiotics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. South Korea Peptide Antibiotics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. Europe Peptide Antibiotics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Peptide Antibiotics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Peptide Antibiotics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Spain Peptide Antibiotics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Peptide Antibiotics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. United Kingdom Peptide Antibiotics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. North America Peptide Antibiotics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Peptide Antibiotics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Mexico Peptide Antibiotics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Canada Peptide Antibiotics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. South America Peptide Antibiotics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Peptide Antibiotics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Peptide Antibiotics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Peptide Antibiotics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Peptide Antibiotics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Peptide Antibiotics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Peptide Antibiotics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Peptide Antibiotics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Peptide Antibiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Pfizer Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Merck & Co., Inc.
• 16.3. AbbVie Inc
• 16.4. GSK Plc
• 16.5. Sandoz International GmbH
• 16.6. Xellia Pharmaceuticals
• 16.7. AuroMedics Pharma LLC
• 16.8. The Menarini Group
• 16.9. Teva Pharmaceutical Industries Ltd.
• 16.10.Novartis AG

17. Strategic Recommendations

18. About Us & Disclaimer